BiotechTube
Home/GeneVentiv Therapeutics/Damon R. Race
DR

Damon R. Race

CEO

GeneVentiv Therapeutics

Therapeutic Areas

Rare Genetic DiseasesHematologyMetabolic Disorders

GeneVentiv Therapeutics Pipeline

DrugIndicationPhase
GENV-HEMHemophilia (including patients with inhibitors)Pre-clinical
GENV-002Pompe Disease (Infantile-Onset and Late-Onset)Pre-clinical

Leadership Team at GeneVentiv Therapeutics

PM
Paris Margaritis
CSO
CL
Chengwen Li
Co-Founder, Scientific Advisor
View full GeneVentiv Therapeutics profile